Waldenstrom Macroglobulinemia - MedHelps Waldenstrom Macroglobulinemia Center for Information, Symptoms, Resources, Treatments and Tools for Waldenstrom Macroglobulinemia. Find Waldenstrom Macroglobulinemia information, treatments for Waldenstrom Macroglobulinemia and Waldenstrom Macroglobulinemia symptoms.
Waldenstroms Macroglobulinemia Symptom: A few patients dont have side effects. For the individuals who have side effects, the most well-known ones are shortcoming, serious weakness, seeping from the nose or gums, weight reduction, and wounds or other skin sores. Seriously large amounts of IgM can prompt hyperviscosity disorder, in which the blood turns out to be unusually thick. Waldenstroms Macroglobulinemia Symptoms of this disorder incorporate visual issues (e.g., obscuring or loss of vision) and neurological issues (e.g., migraine, discombobulation, vertigo). Amid a physical exam, a specialist might likewise discover swelling of the lymph hubs, spleen, and/or liver.. Waldenstroms Macroglobulinemia Causes:. Waldenstroms macroglobulinemia is a consequence of a condition called lymphoplasmacytic lymphoma. The reason for the overproduction of the IgM counter acting agent is obscure, yet specialists trust it is made by lymphoma cells. Overproduction of Waldenstroms Macroglobulinemia Causes ...
Certain risk factors may increase your chance of developing Waldenstrom macroglobulinemia. This guide will help you learn about possible causes of Waldenstrom macroglobulinemia.
... On-line free medical diagnosis assistant. Ranked list of possible diseases from either several symptoms or a full patient history. A similarity measure between symptoms and diseases is provided.
Waldenstroms macroglobulinemia is a rare type of cancer. Learn about waldenstroms macroglobulinemia prognosis, diagnosis, symptoms and treatment.
The following disease types are eligible: transformed lymphomas: diffuse large B cell lymphoma, mantle cell lymphoma, follicular lymphoma grade III; precursor B lymphoblastic leukemia/lymphoma; mediastinal (thymic) large B-cell lymphoma; Burkitt lymphoma/leukemia; precursor T-lymphoblastic leukemia/lymphoma; primary cutaneous anaplastic large cell lymphoma; anaplastic large cell lymphoma - primary systemic type; small lymphocytic lymphoma/chronic lymphocytic leukemia; follicular lymphoma, grades 1, 2; extranodal marginal zone B-cell lymphoma of MALT type; nodal marginal zone B-cell lymphoma; splenic marginal zone B-cell lymphoma; peripheral T cell lymphoma, unspecified; anaplastic large cell lymphoma (T and null cell type); lymphoplasmacytic lymphoma (Waldenstrom Macroglobulinemia); CNS lymphoma; post transplant lymphoproliferative disorders; mycosis fungoides/Sezary syndrome; primary effusion lymphoma; blastic NK-cell lymphoma; adult T-cell leukemia/lymphoma; extranodal NK/T-cell lymphoma, ...
Waldenstrom macroglobulinemia is a rare cancer and is characterized by high level of immunoglobulin M (IgM) in the serum, which leads to increased serum viscosity, and presence of a lymphoplasmacytic infiltrate in the bone marrow. Waldenstrom macroglobulinemia starts in B cells or B lymphocytes and leads to excess amount of IgM. Treatment options for Waldenstrom macroglobulinemia vary according to symptoms. In the last few years, medical science has made much progress and a number of new treatments for this type of cancer have been introduced. However, very few studies have been done to compare the treatment options and thus, discover the best available option. Hence, there is no single treatment available that works for all patients.
PURPOSE: Allogeneic stem-cell transplantation (alloSCT) is a curative therapeutic option for patients with low-grade lymphoid malignancies. Information regarding alloSCT in Waldenstrom macroglobulinemia (WM) is limited. This study presents the long-term outcome of a large series of patients with WM treated with alloSCT. PATIENTS AND METHODS: A total of 86 patients received allograft by using either myeloablative (MAC; n = 37) or reduced-intensity conditioning (RIC; n = 49) regimens and were retrospectively studied. The median age was 49 years (range, 23 to 64 years); 47 patients had received three or more previous lines of therapy, and eight patients had experienced failure on a prior autologous stem-cell transplantation. A total of 59 patients (68.6%) had chemotherapy-sensitive disease at the time of alloSCT. Median follow-up of the surviving patients was 50 months (7 to 142 months). RESULTS: Nonrelapse mortality (NRM) at 3 years was 33% for MAC and 23% for RIC. The overall response rate was ...
... (WM) is a cancer of the B lymphocytes (a type of white blood cell). WM is associated with the overproduction of proteins called IgM antibodies.
Waldenstrom macroglobulinemia (WM) is a type of non-Hodgkin lymphoma (NHL) that produces large amounts of an abnormal protein (called a macroglobulin). Learn more here.
Waldenstrom macroglobulinemia | Diagnosis and treatment. Cancer: Treatment in Erlangen, Germany ✈. Prices on BookingHealth.com - booking treatment online!
Diagnosis and treatment in Waldenstrom macroglobulinemia (costs for program #126043) ✔ University Hospital Rechts der Isar of the Munich Technical University ✔ Department of Hematology and Oncology ✔ BookingHealth.com
The purpose of this study is to obtain bone marrow and peripheral blood samples, along with clinical data from patients with Multiple Myeloma (MM), Waldenstroms Macroglobulinemia (WM), Smoldering MM, and other lymphoplasmacytic lymphomas (LPL) including but not limited to MGUS and IgG or IgA LPL. These samples will become part of a tissue bank and will be used in ongoing studies to find out more about the causes and biology of MM, WM and LPL; to identify what factors result in normal cells becoming cancer; to determine how to improve treatment options; to study how the immune system identifies abnormal cells; and to evaluate the immune function in these diseases. The investigators will also study the tumor cells at the level of the participants genes to develop treatment strategies as well as to better understand how biologic differences affect patient outcomes ...
What reasons Waldenstroms Macroglobulinemia like numerous different diseases are obscure despite the fact that it is trusted that a change in DNA could be a reason. Despite this absence of assurance on the Waldenstrom Macroglobulinemia Causes there are thought to be elements which improve the probability of building up the malady. The lions share of instances of waldenstroms macroglobulinemia happen in those beyond 50 years old and the normal time of event is 61. Occurrence of the ailment is twice as much in men than ladies. The condition is likewise acquired which implies that those with family who have Waldenstroms or a kind of lymphatic tumor are more prone to get the condition.. Symptoms A first conclusion of Waldenstroms is mind boggling in light of the fact that there is typically an unlucky deficiency of Waldenstroms Macroglobulinemia Symptoms right off the bat. Typically the first sign of Waldenstroms originates from routine examinations indicating atypical results. These ...
Waldenstroms macroglobulinemia (WM) is an uncommon low-grade lymphoma. Cognitive impairment due to central nervous system infiltration by lymphoplasmocytoid cells (Bing-Neel syndrome) has been rarely reported. We describe a 54-year-old man who was referred to a memory disorder clinic with a 9-month history of clinically obvious nonfluent aphasia and WM. He underwent extensive neuropsychological testing, clinical examination and structural and functional brain imaging. The diagnosis of the diffuse form of the Bing-Neel syndrome was supported by abnormal lymphoid cells found in the cerebrospinal fluid. Structural and functional brain imaging revealed impairment of brain areas due to white matter changes and subsequent functional deficits mimicking the neuropsychological syndrome encountered in progressive nonfluent aphasia. The diffuse form of Bing-Neel syndrome and neurological deficits are assumed to be the result of leptomeningeal infiltration by malignant cells and/or neoplastic vascular ...
This research study is studying Ulocuplumab combined with ibrutinib as a possible treatment for symptomatic Waldenstroms Macroglobulinemia (WM).
Waldenstroms Macroglobulinemia is a rare disorder that causes the generation of irregular B-lymphocytes, white platelets. It has a portion of the same elements of both lymphomas and of numerou...
TY - JOUR. T1 - Small-intestinal involvement in Waldenstroms macroglobulinemia - Case report and review of the literature. AU - Brandt, Lawrence J.. AU - Davidoff, Allen. AU - Bernstein, Leslie H.. AU - Biempica, Luis. AU - Rindfleisch, Burton. AU - Goldstein, Mervyn L.. PY - 1981/2. Y1 - 1981/2. UR - http://www.scopus.com/inward/record.url?scp=0019391786&partnerID=8YFLogxK. UR - http://www.scopus.com/inward/citedby.url?scp=0019391786&partnerID=8YFLogxK. U2 - 10.1007/BF01312238. DO - 10.1007/BF01312238. M3 - Article. C2 - 6780283. AN - SCOPUS:0019391786. VL - 26. SP - 174. EP - 180. JO - Digestive Diseases and Sciences. JF - Digestive Diseases and Sciences. SN - 0163-2116. IS - 2. ER - ...
TY - JOUR. T1 - Defining lymphoplasmacytic lymphoma. T2 - Does MYD88L265P define a pathologically distinct entity among patients with an IgM paraprotein and bone marrow-based low-grade b-cell lymphomas with plasmacytic differentiation?. AU - Fang, Hong. AU - Kapoor, Prashant. AU - Gonsalves, Wilson. AU - Frederick, Lori A.. AU - Viswanatha, David. AU - Howard, Matthew T.. AU - He, Rong. AU - Morice, William G.. AU - McPhail, Ellen. AU - Greipp, Patricia T. AU - Ansell, Stephen Maxted. AU - Kyle, Robert A.. AU - Gertz, Morie. AU - Paludo, Jonas. AU - Abeykoon, Jithma. AU - King, Rebecca. PY - 2018/7/3. Y1 - 2018/7/3. N2 - Objectives Lymphoplasmacytic lymphoma (LPL) remains a poorly defined entity, even with the discovery of MYD88 L265P mutations and association with Waldenström macroglobulinemia (WM). Among bone marrow (BM)-based, low-grade B-cell lymphoma with plasmacytic differentiation (LGBLPD) and immunoglobulin M (IgM) paraproteins, we sought to determine whether MYD88 L265P defines a ...
Activating mutations in MYD88 and CXCR4 mutations are present in 95-97% and 40-45% of previously untreated patients with Waldenströms macroglobulinemia, respectively. MYD88 mutations trigger malignant cell growth through Brutons Tyrosine Kinase and Hematopoietic Cell Kinase, both targets of ibrutinib (Yang et al, Blood 2013; Blood 2016). CXCR4 mutations confer in vitro as well as clinical evidence of resistance in previously treated WM patients to ibrutinib (Cao et al, Leukemia 2014, Treon et al NEJM 2015). Ibrutinib produces overall and major [partial response (PR) or better] responses in 90% and 70-75% of previously treated WM patients (Treon et al, NEJM 2015; Dimopoulos et al, Lancet Oncol. 2017). The activity of ibrutinib in untreated, symptomatic WM patients is not known. We therefore investigated the activity and safety of ibrutinib in this patient population. Thirty patients were enrolled in this study. Key baseline characteristics were as follows: median age 67 (range 43-83 yrs); 23 ...
Waldenstroms Macroglobulinemia. indolent lymphoma occurs > 30years, usually > 60years characterised by proliferation of lymphoplasmatic and plasma cells monoclonal immunoglobulin M. Waldenstroms Macroglobulinemia - clinical presentation. asymptomatic symptomatic ...
What is Waldenstrom's macroglobulinemia, who gets it, what are the symptoms, and how is it treated initially and when it relapses?
To the Editor: Purine analogues, including cladribine (2-chlorodeoxyadenosine), are increasingly used in the treatment of Waldenstroms macroglobulinemia and other hematologic cancers. (1) Cladribine can cause profound immunosuppression, lymphopenia, and increased susceptibility to opportunistic infections. (2) We report on a patient with Waldenstroms macroglobulinemia in whom an Epstein-Barr virus (EBV)-associated diffuse large-cell lymphoma developed after treatment with cladribine. A 69-year-old woman received the diagnosis of Waldenstroms macroglobulinemia with IgM kappa in 1991. Because of the progression of the disease, treatment with standard doses of cladribine was initiated in June 1994 and repeated in August 1994. The patient had a remarkable response, with alleviation of her symptoms and more than 90 percent reduction of the serum paraprotein level. Five months after the completion of treatment with cladribine, pain developed in the right hip, and a right acetabular lytic lesion was ...
Waldenströms macroglobulinemia (WM), also known as lymphoplasmacytic lymphoma, is a type of cancer affecting two types of B cells, lymphoplasmacytoid cells and plasma cells. Both cell types are white blood cells. WM is characterized by having high levels of a circulating antibody, immunoglobulin M (IgM), which is made and secreted by the cells involved in the disease. WM is an "indolent lymphoma" (i.e., one that tends to grow and spread slowly) and a type of lymphoproliferative disease which shares clinical characteristics with the indolent non-Hodgkin lymphomas. WM is commonly classified as a form of plasma cell dyscrasia. Similar to other plasma cell dyscrasias that, for example, lead to multiple myeloma, WM is commonly preceded by two clinically asymptomatic but progressively more pre-malignant phases, IgM monoclonal gammopathy of undetermined significance (i.e. IgM MGUS) and smoldering Waldenströms macroglobulinemia. The WM spectrum of dysplasias differs from other spectrums of plasma ...
CHAPTER 108 WALDENSTRÖM MACROGLOBULINEMIA Williams Hematology CHAPTER 108 WALDENSTRÖM MACROGLOBULINEMIA THOMAS J. KIPPS Definition and History Lymphoplasmacytic Neoplasms B-Lymphocytic Neoplasms Essential Monoclonal Macroglobulinemia Etiology and Pathogenesis Etiology Pathogenesis Clinical Features The Hyperviscosity Syndrome Laboratory Findings Serum Immunoglobulin and Blood Viscosity Blood and Marrow Cells Disorders of Hemostasis Renal Abnormalities Differential Diagnosis Therapy, Course, and Prognosis…
Individualized treatment for Waldenström's macroglobulinemia (WM) has become a feasible strategy with improved understanding of the disease and expanded treatment options.
Export Date: 18 February 2017References: Treon, S.P., Waldenströms macroglobulinemia: an indolent B-cell lymphoma with distinct molecular and clinical features (2013) Hematol Oncol, 31, pp. 76-80;Dimopoulos, M.A., Kastritis, E., Owen, R.G., Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus (2014) Blood, 124, pp. 1404-1411; Buske, C., Leblond, V., How to manage Waldenströms macroglobulinemia (2013) Leukemia, 27, pp. 762-772; Buske, C., Sadullah, S., Kastritis, E., Treatment and outcome patterns in patients with relapsed Waldenströms macroglobulinemia: development of a large observational Pan-European data platform (2016), The 21st European Hematology Association Annual Congress; Copenhagen, Denmark; June 9-12,. Abstr E1275Castillo, J.J., Kanan, S., Meid, K., Manning, R., Hunter, Z.R., Treon, S.P., Rituximab intolerance in patients with Waldenström macroglobulinaemia (2016) Br J Haematol, 174, pp. 645-684; Treon, S.P., ...
Introduction. Waldenström macroglobulinemia is defined by the World Health Organization and the International Waldenströms Working Group as the presence of bone marrow lymphoplasmacytic lymphoma associated with a monoclonal IgM protein of any size. The bone marrow morphology shows both CD38 expressing plasma cells and CD20 expressing lymphoplasmacytic cells. A monoclonal protein is invariably visible on the serum protein electrophoresis. Immunofixation identifies an IgM heavy chain. One of the defining syndromes of Waldenström macroglobulinemia is the development of hyperviscosity due to the impact of pentameric IgM on the flow of serum. The most common signs of hyperviscosity are oronasal bleeding or blurred vision secondary to retinal hemorrhage.. IgM monoclonal serum proteins represent 18% of all monoclonal proteins seen. Since monoclonal gammopathy of undetermined significance (MGUS) is seen in 3% of adults over the age of 70, 1 adult in 200 will have an IgM monoclonal protein. However, ...
NOTE: The study is based on active ingredients and brand name. Other drugs that have the same active ingredients (e.g. generic drugs) are NOT considered.. WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.. DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only, and has not been supported by scientific studies or clinical trials unless otherwise stated. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.. You may report adverse side effects to the FDA at http://www.fda.gov/medwatch/ or 1-800-FDA-1088 (1-800-332-1088).. If you ...
Purpose: Everolimus inhibits mTOR, a component of PI3K/AKT prosurvival signaling triggered by MYD88 and CXCR4-activating mutations in Waldenstrom macroglobulinemia.. Experimental design: We evaluated everolimus in a prospective, multicenter study of 33 symptomatic, previously untreated Waldenstrom macroglobulinemia patients. Intended therapy consisted of everolimus (10 mg/day) until progression or unacceptable toxicity. Dose deescalation was permitted. The study was registered at www.clinicaltrials.gov (NCT00976248).. Results: At best response, median serum IgM levels declined from 4,440 to 1,360 mg/dL (P , 0.0001), median hemoglobin rose from 10.8 to 12 g/dL (P = 0.001), and median bone marrow disease burden declined from 75% to 52.5% in serially biopsied patients. The ORR and major response rates were 72.7% and 60.6%, respectively. Among genotyped patients, nonresponders associated with wild-type MYD88 and mutated CXCR4 status. Median time to response was 4 weeks. Discordance between serum IgM ...
TY - JOUR. T1 - Molecular pathogenesis of Waldenströms macroglobulinemia. AU - Braggio, Esteban D. AU - Philipsborn, Casey. AU - Novak, Anne J. AU - Hodge, Lucy. AU - Ansell, Stephen Maxted. AU - Fonseca, Rafael. PY - 2012/9/1. Y1 - 2012/9/1. N2 - Waldenströms macroglobulinemia is an indolent, lymphoproliferative disease, characterized by a heterogeneous lymphoplasmacytic bone marrow infiltrate and high immunoglobulin M production. While technological advances over the past several decades have dramatically improved the possibilities of studying the molecular basis of Waldenströms macroglobulinemia, the pathogenesis of the disease remains fragmented. Undoubtedly, research has been successful in uncovering underlying aberrations and deregulated mechanisms in this disease, providing useful information for identifying biomarkers for disease diagnosis, risk stratification and therapeutic intervention, but there is still a long way to go before the pathogenesis of Waldenströms ...
Neurology news, research and treatment studies for epilepsy, neurodegenerative disorders, patients with MS and other brain and central nervous system disorders and diseases.
Get information, facts, and pictures about Waldenstroms Macroglobulinemia at Encyclopedia.com. Make research projects and school reports about Waldenstroms Macroglobulinemia easy with credible articles from our FREE, online encyclopedia and dictionary.
There was a recurring theme of hope and progress for Waldenstrom macroglobulinemia patients at ASH 2019. Watch as Dr. James Berenson explains how Waldenstrom patients are benefiting from treatment options developed for myeloma and lymphoma.
As Waldenstroms macroglobulinaemia is incurable, treatment is only indicated in symptomatic cases. Plasmapheresis is effective for short term control of hyperviscosity and its associated symptoms. The oral alkylating agent chlorambucil is effective in controlling the disease and there are reports of its successful use in cases with pulmonary involvement,4 5 although treatment for 12 months may be required before an adequate response is obtained. Treatment with combinations of chemotherapeutic agents has also been found to be effective.. In view of her hyperviscosity, our patient was admitted to hospital for plasmapheresis, ultimately requiring eight sessions. As treatment for her underlying macroglobulinaemia she received chemotherapy with six cycles of the nucleoside analogue fludarabine (25 mg/m2daily for five days, repeated every four weeks). There was a marked improvement in the appearances of the chest radiograph (see fig 1below) and the patient is now symptom free. Plasma viscosity fell ...
A chronic low-grade (indolent) type of lymphoma due to a malignant clone of plasma cells. These plasma cells multiply out of control, invade the bone marrow, lymph nodes, and spleen, and characteristically produce huge amounts of a large-sized antibody called macroglobulin or IgM. The excess IgM causes the blood to be hyperviscous (to thicken). Waldenstrom macroglobulinemia can occur in younger people but is usually seen in people over age 65. The disease is more common among men than women and among whites than blacks. Signs and symptoms of the disease may include enlarged lymph nodes or spleen (splenomegaly), fatigue, headaches, weight loss, a tendency to bleed easily, visual problems, confusion, dizziness, and loss of coordination. The symptoms are largely due to the thickening of the blood. In extreme cases, the increased concentration of IgM in the blood can lead to heart failure. The treatment depends upon the viscosity of the patients blood. Patients with pronounced hyperviscosity ...
Waldenströms macroglobulinaemia (WM), lymphoplasmacytic lymphoma, is an indolent lymphoid neoplasm, which occurs mainly in older patients.. It is characterised by the presence of an IgM paraprotein and a bone marrow infiltrate with monoclonal plasmacytoid lymphocytes.. Hyperviscosity and progressive bone marrow failure are common complications of WM.. Full blood count, Blood film, White cell count differential, Erythrocyte sedimentation rate, Bone marrow biopsy (bone marrow aspiration/trephine biopsy), Protein, Albumin, Protein electrophoresis, Paraprotein typing (and quantitation), Immunoglobulins (G, A, M).. See also Lymphoma (classification), Lymphoproliferative disorders and Paraproteinaemia. ...
Cells. The WM cell lines (BCWM.1; WM-WSU) and IgM-secreting low-grade lymphoma cell lines (MEC-1; RL) were used in this study. BCWM.1 is a recently described WM cell line that was developed from a patient with untreated WM (18). WSU-WM was kindly provided by Dr. Al Katib (Wayne State University, Detroit, MI). MEC-1 was a gift from Dr. Kay (Mayo Clinic, Rochester, MN). RL was purchased from the American Tissue Culture Collection. All cell lines were cultured at 37°C in RPMI 1640 containing 10% fetal bovine serum (Sigma Chemical), 2 mmol/L of l-glutamine, 100 units/mL of penicillin, and 100 μg/mL of streptomycin (Life Technologies).. Primary WM cells were obtained from bone marrow (BM) samples from previously treated WM patients, using CD19+ microbead selection (Miltenyi Biotec) with ,90% purity as confirmed by flow cytometric analysis with monoclonal antibody reactive to human CD20-PE (BD-Bioscience). Peripheral blood mononuclear cells (PBMC) were obtained from healthy subjects by ...
The main goal of this clinical research study is to learn if Velcade ® (bortezomib) given with rituximab can help to control WM. This drug combination will allow researchers to collect your stem cells in case it is possible to transplant the stem cells as treatment if your WM gets worse. Researchers will also look at the safety and tolerability of this drug combination followed by treatment with other drug combinations.
LRF Updates on Lymphoma and Treatment Options Thursday, February 8 6:00 PM - 8:30 PM San Diego Marriott La Jolla 4240 La Jolla Village Drive La Jolla, CA 92037 Speaker: Thomas Kipps, MD, PhD Contact: [email protected], 800-500-9976 *This program is offered free-of-charge to members of the lymphoma community; however, pre-registration is required. Dinner will be provided for all registered attendees.
Lymphoma Research Foundation Ask the Doctor Lymphoma Program Partner Meeting Thursday, February 15 6:00 PM - 8:30 PM Embassy Suites Dallas Near the Galleria 14021 Noel Road Dallas, TX 75240 Speaker: Thomas Froehlich, MD, MSHA
Abstract. Background While kidney disease (KD) is a well described complication of multiple myeloma (MM), occurring in up to 40% of patients, the incidence, pa
0220]Strain CNB476 was grown in a 500-ml flask containing 100 ml of the first vegetative medium consisting of the following per liter of deionized water: glucose, 4 g; Bacto tryptone, 3 g; Bacto casitone, 5 g; and synthetic sea salt (Instant Ocean, Aquarium Systems), 30 g. The first seed culture was incubated at 28 degree C. for 3 days on a rotary shaker operating at 250 rpm. Five ml of the first seed culture was inoculated into a 500-ml flask containing 100 ml of the second vegetative medium consisting of the following per liter of deionized water: starch, 10 g; yeast extract, 4 g; peptone, 2 g; ferric sulfate, 40 mg; potassium bromide, 100 mg; calcium carbonate, 1 g; and sodium bromide, 30 g. The second seed cultures were incubated at 28° C. for 7 days on a rotary shaker operating at 250 rpm. Approximately 2 to 3 gram of sterile Amberlite XAD-7 resin were added to the second seed culture. The second seed culture was further incubated at 28° C. for 2 days on a rotary shaker operating at 250 ...
Pain management information for pain medicine healthcare professionals in treating and caring for their patients. Clinical Pain Advisor offers news, case studies and more.
Waldenström macroglobulinemia (WM) is a rare, slow-growing cancer. It is a form of non-Hodgkin lymphoma. WM is also known as lymphoplasmacytic lymphoma. WM…
Kapoor P, Ansell SM, Fonseca R, Chanan-Khan A, Kyle RA, Kumar SK, Mikhael JR, Witzig TE, Mauermann M, Dispenzieri A, Ailawadhi S, Stewart AK, Lacy MQ, Thompson CA, Buadi FK, Dingli D, Morice WG, Go RS, Jevremovic D, Sher T, King RL, Braggio E, Novak A, Roy V, Ketterling RP, Greipp PT, Grogan M, Micallef IN, Bergsagel PL, Colgan JP, Leung N, Gonsalves WI, Lin Y, Inwards DJ, Hayman SR, Nowakowski GS, Johnston PB, Russell SJ, Markovic SN, Zeldenrust SR, Hwa YL, Lust JA, Porrata LF, Habermann TM, Rajkumar SV, Gertz MA, Reeder CB. Diagnosis and Management of Waldenstrom Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines 2016. JAMA Oncol. 2017 Sep 1; 3 (9):1257-1265 ...
Waldenströms macroglobulinaemia is an uncommon, low grade, small cell lymphoma with monoclonal IgM production. This protein accounts for the increased plasma viscosity often seen in this disease, and causes some of the most frequent symptoms. Other less common protein complications include cold agglutinin haemolytic anaemia, peripheral neuropathy, amyloidosis, and cryoglobulinaemia.5. The term cryoglobulinaemia refers to the presence in the serum of one or more immunoglobulins that precipitate reversibly at a temperature below 37°C. According to Brouet et al,4 cryoglobulins can be classified on the basis of their immunoglobulin composition as type I, consisting of a monoclonal immunoglobulin alone; type II, as a mixture of monoclonal and polyclonal immunoglobulins; and type III, consisting of polyclonal immunoglobulins. They are found in small quantities in normal serum,6 but in large concentrations in many pathological conditions. Whereas type III cryoglobulinaemia is mainly noted as the ...
The U.S. Food and Drug Administration (FDA) has approved ibrutinib (Imbruvica) plus rituximab (Rituxan) for the treatment of adult patients with Waldenströms macroglobulinemia (WM). With this approval, the ibrutinib prescribing information now includes combination use with rituximab, representing the first and only chemotherapy-free combination treatment specifically indicated for the disease. Ibrutinib- a first-in-class Brutons tyrosine kinase (BTK) inhibitor-was first approved as a single agent therapy for WM in January 2015.. WM is a rare, slow-growing and incurable form of non-Hodgkin lymphoma with limited treatment options. WM typically affects older adults and is primarily found in the bone marrow, although lymph nodes and the spleen also may be affected. In the United States, there are about 2,800 new cases of WM each year.. iNNOVATE Trial. The approval is supported by data from the phase III iNNOVATE trial, which evaluated ibrutinib in combination with rituximab vs rituximab alone in ...
The following websites contain valuable information regarding the research and treatment of Waldenstroms Macroglobulinemia: Please visit our main program website: Bing Center for Waldenstroms Research. This site contains information on the latest treatment recommendations, abstracts, news and events, current and pending clinical trials and participating institutions, basic research, and publications, as well as photos and brief bios of the Bing Center staff.. Also feel free to visit our WM Workshop Website where you will find information about our recent and upcoming conferences.. ...
The following websites contain valuable information regarding the research and treatment of Waldenstroms Macroglobulinemia: Please visit our main program website: Bing Center for Waldenstroms Research. This site contains information on the latest treatment recommendations, abstracts, news and events, current and pending clinical trials and participating institutions, basic research, and publications, as well as photos and brief bios of the Bing Center staff.. Also feel free to visit our WM Workshop Website where you will find information about our recent and upcoming conferences.. ...